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Abstract
Background—Macrophage carried nanoformulated catalase (“nanozyme”) attenuates
neuroinflammation and protects nigrostriatal neurons from 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine intoxication. This is facilitated by effective enzyme transfer from blood borne
macrophages to adjacent endothelial cells and neurons leading to the decomposition of reactive
oxygen species.
Methods—We now examine the intra- and intercellular trafficking mechanisms of nanozymes.
Results—In macrophages, nanozymes are internalized mainly by clathrin mediated endocytosis
then traffic to recycling endosomes. The enzyme is subsequently released in exosomes facilitated
by bridging conduits. Nanozyme transfer from macrophages to adjacent cells by endocytosis-
independent mechanisms diffusing broadly throughout the recipient cells. In contrast,
macrophage-free nanozymes are localized in lysosomes following endocytic entry.
Conclusion—Facilitated transfer of nanozyme from cell to cell can improve neuroprotection
against oxidative stress commonly seen during neurodegenerative disease processes.
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The pathobiology of neurodegenerative disorders, including Parkinson’s and Alzheimer’s
diseases (PD and AD), is linked to microglial activation and its secretion of neurotoxic
factors. These include reactive oxygen and nitrogen species (ROS and RNS) leading to
oxidative stress and neuronal injuries [1–4]. Oxidative stress affects neuronal, astrocyte, and
microglia function by inducing ion transport, calcium mobilization, and activating apoptotic
programs. Apoptosis and excitotoxicity are principal causes of mitochondrial-induced
neuronal death [5]. Indeed, the mitochondrial respiratory chain affects oxidative
phosphorylation and is responsible for ROS production. Such pathways lead to neuronal
demise and underlie the pathobiology of PD and AD [6]. The lack of natural antioxidants
(glutathione and superoxide dismutase) and iron in the substantia nigra are specifically
associated with the pathobiology of PD [7–9]. Thus, removing ROS and affecting
mitochondria function through targeted delivery of redox enzymes could attenuate disease
progression [10]. On balance, antioxidants when administered as therapeutic agents fail to
alter the course of PD-associated neurodegeneration [11]. We posit that such failures may
limit the delivery of antioxidants at disease sites. To this end, we developed a cell-based
delivery system to bring nanoformulated catalase to affected brain regions in the 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine model (MPTP) of PD [12, 13]. The system rests
in the abilities of blood borne macrophages to carry antioxidant proteins across the blood-
brain barrier (BBB) to affected brain subregions. To preclude macrophage-mediated enzyme
degradation, catalase was packaged into a block ionomer complex with a cationic block
copolymer, poly(ethyleneimine)-poly(ethylene glycol). First, we reported that both
components of the formulation, nanozyme and macrophages, were detected in the brain area
of the MPTP-intoxicated animals [14]. Next, the formulation demonstrated efficient
protection of enzymatic activity along with relatively high loading and release rates from
bone marrow-derived macrophages (BMM) and limited cytotoxicities [14].
We propose that several independent processes serve to improve nanozyme-loaded
macrophage therapeutics [15]. First, drug-loaded macrophages reach CNS inflammation
sites and release catalase, and as such permit targeted therapeutic tissue-specific delivery
[13]. Second, nanozyme-loaded macrophages permit sustained release of catalase allowing
enzyme to enter the brain, independent of carrier cells. Third, catalase released from
immunocytes such as macrophages can suppress peripheral leukocyte activation and protect
nigrostratial neurons at a distance. Fourth, drug-loaded BMM transfer catalase nanoparticles
to brain microvessel endothelial cells, neurons and astrocytes [15] and increase BBB
penetration and ROS decomposition. Such events occur through endocytosis-independent
mechanisms including fusion of cellular membranes, macrophage bridging conduits
engagements of neighboring cells, and nanozyme lipid coating facilitating nanozyme
transfer from carrier cells to target recipient cells [15]. Taken together, cell-to-cell transfer
of nanozyme improves therapeutic outcomes afforded by catalase in PD mouse models. In
the present study we uncovered the mechanisms for nanozyme trafficking in BMM and its
transfer to endothelial cells and neurons. Nanozyme trafficking in and between cells can
facilitate neuroprotective responses and provide insights into how cell-carried
nanoformulations can inevitably improve clinical outcomes for neurodegenerative diseases.
MATERIALS & METHODS
Reagents
Catalase from bovine liver erythrocytes was provided by Calbiochem (San Diego, CA).
Methoxypolyethylene glycol epoxy (Me-PEG-epoxy) was purchased from Shearwater
Polymer Inc. (Huntsville, AL). Polyethyleneimine-poly(ethylene glycol) (PEI (2K)-PEG
(10K)) was synthesized as described [12] by conjugation of PEI and Me-PEG-epoxy.
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LysoTracker Green, MitoTracker Green, and ERTracker Green were obtained from
Molecular Probes (Carlsbad, CA). Lipopolysaccharides (LPS), Sephadex G-25, Triton
X-100, and trypsin were purchased from Sigma-Aldrich (St. Louis, MO). Cell dyes 1,1'-
dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine perchlorate (DiD) and 3,3'-dilinoleyl-
oxacarbocyanine perchlorate (DiO) were purchased from Invitrogen. FITC-conjugated
mouse antibodies to EEA1 (early endosomes), and LAMP1 (lysosomes); and unconjugated
mouse antibodies to Rab11 (recycling endosomes), and Alexa Fluor-405-conjugated anti-
CD14 were purchased from BD Biosciences (San Diego, CA). Mouse monoclonal
antibodies to RAB 7 (late endosomes) were obtained at Abcam (Cambridge, MA).
Secondary goat antimouse FITC-conjugated antibodies were purchased from Invitrogen
Interferon gamma (INF-γ) was purchased from Peprotech Inc. (RockyHill, NJ).
Catalase Nanozyme
The polycomplex was produced by mixing catalase and a block copolymer, PEI-PEG, which
form nanoparticles with an enzyme-polyion complex core and PEG corona [12, 13] at
charge ratio (Z = 1). This was calculated by dividing the amount of amino groups in the
block copolymer protonated at pH 7.4 [16] by the total amount of Gln and Asp in catalase.
For confocal studies, catalase was labeled with Alexa Fluor 647 Protein Labeling Kit
(Invitrogen), or rhodamine isothiocyanate (RITC) [12]. Labeled catalase was purified from
low molecular weight residuals by gel filtration on a Sephadex G-25 column, and
lyophilized.
Cells
Bone marrow-derived macrophages (murine macrophages) were extracted from femurs of
C57Bl/6 male mice 6–7 weeks of age according to previously published protocols [17] and
cultured for 12 days in DMEM medium (Invitrogen) supplemented with 1,000 U/mL
macrophage colony-stimulating factor (MCSF), a generous gift from Pfizer Pharmaceuticals,
Cambridge, MA). Murine macrophages were collected after 12 – 14 days of culture. Human
monocyte-derived macrophages were obtained from leukopaks of healthy donors, purified
by countercurrent centrifugal elutriation [18] and cultured with MCSF.
Mouse catecholaminergic CATH.a neurons were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA), and cultured in RPMI-1640 medium
supplemented with 8% normal horse serum (NHS), 4% fetal bovine serum (FBS), and 1%
penicillin-streptomycin. Cultures were maintained in a humidified incubator at 37°C and 5%
CO2. CATH.a neurons were differentiated by adding 1 mM of N6,2’-O-dibutyryladenosine
3’,5’-cyclic monophosphate sodium salt (dbcAMP, Sigma-Aldrich) to the culture media
every other day for 6–8 days.
Primary human brain microvessel endothelial cells (HBMEC) were isolated from brain
tissue obtained during surgical removal of epileptogenic cerebral cortex in adult patients,
and were provided by Drs Marlys Witte and Michael Bernas (University of Arizona,
Tucson, AZ). Routine evaluation for expression of von Willebrand factor (VWF), Ulex
europeus lectin, and CD31 demonstrated that HBMECs were more than 99% pure.
HBMECs were seeded in the collagen I-coated chamber of slides (500,000 cells/well), or 6-
well tissue culture plates, and cultured to confluence in Microvascular Endothelial Cell
Growth Medium-2 (EGM-2) BulletKit media (Cambrex, Walkersville, MD) supplemented
with 5% fetal bovine serum (FBS). Only cells at passage 1 to 4 were used in this study.
Confocal Microscopy
Human or mouse bone marrow-derived macrophages grown in chamber slides (500,000
cells/well) [19] were exposed to Alexa Fluor 647-labeled nanozyme (50 µg/ml, Z=1) for
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different time points (5 min, 15 min, 30 min, 60 min) at 37°C. For entrance pathway
evaluation, living cells were stained with FITC-labeled transferrin (Tf, clathrin-mediated
endocytosis, 25 µg/ml, 15 min), or cholera toxin B (CTB, caveolin-mediated endocytosis, 25
µg/ml, 15 min); or fixed with 4% PFA in 0.03 M sucrose for 20 min, and permeabilized with
0.2% saponin in 0.03 M sucrose for 5 min cells were stained with FITC-conjugated mouse
anti-clathrin heavy chain antibodies (BD Transduction Laboratories), or Cy3 labeled anti-
caveolin-1 antibodies (Sigma-Aldrich) according to manufacturer’s protocol. For
intracellular trafficking studies, cells were stained with antibodies to early, late, or recycling
endosomes, and lysosomes. For this purpose, loaded with nanozyme cells were rinsed three
times with 1% BSA in PBS, fixed and permeabilized. Following permeabilization, cells
were incubated with FITC-conjugated EEA1 or LAMP 1 monoclonal antibodies (5 µg/ml, 1
hour, BD Transduction Laboratories), or unconjugated primary mouse monoclonal
antibodies, Rab7 or Rab11 (5 µg/ml, 30 min, BD Transduction Laboratories). Cells treated
with unconjugated primary mouse antibody were stained with FITC-conjugated secondary
goat anti-mouse immunoglobulin G (5 µg/ml, 1 hour, Sigma-Aldrich). To distinguish
between the carrier cells and target cells, human macrophages were labeled with Alexa
Fluor-405-conjugated anti-CD14. For release mechanism evaluation, macrophages were co-
stained with Alexa Fluor-488 mouse anti-β-tubulin (clone 5H1) or Alexa Fluor-488-
phalloidin (BD Biosciences) for tubulin and actin visualization, respectively. Labeled cells
were examined by a confocal fluorescence microscopic system ACAS-570 (Meridian
Instruments, Okimos, MI) with argon ion laser and corresponding filter set. Digital images
were obtained using the CCD camera (Photometrics) and Adobe Photoshop software.
Quantification of immunostaining was performed with ImageJ software, utilizing JACoP
plugins [20] to calculate Pearson’s colocalization coefficients [21]. Comparison was
performed on 7–10 sets of images acquired with the same optical settings.
Nanozyme Macrophages Loading and Release
To evaluate the involvement of different types of endocytosis, murine macrophages grown
in 24-well plates (2.5 × 106 cells/plate) [19, 22] were pre-incubated with serum free, phenol
red free DMEM, containing inhibitors of clatrin-mediated endocytosis, sucrose (0.25 M, 20
min) or dansylcaverdine (0.2 mM, 10 min); inhibitors of caveolea-mediated endocytosis,
fillipin (1 µg/ml, 20 min) or nystatin (50 µg/ml15 min); an inhibitor of phagocytosis,
cytochalasin b (10 µg/ml, 2 hours); an inhibitor of scavenger receptor, polyinosinis acid (10
µg/ml, 30 min); an inhibitor of pinocytosis, colchicine (100 µg/ml, 2 hours); or an inhibitor
of macropinocytosis, rotterin (2 µM, 30 min). Following pre-incubation, the cells were
treated with RITC-labeled nanozyme (0.5 mg/ml) in the presence of the corresponding
inhibitor or assay buffer for one hour, washed, lysed with 1% Triton X100, and levels of
fluorescence in each sample were measured by Shimadzu RF5000 fluorescent
spectrophotometer. For release studies, murine macrophages loaded with nanozyme for one
hour were incubated with fresh assay buffer for another hour; then the media was collected
and the levels of released nanozyme were detected by fluorospectrophotometry. To evaluate
the effect of activation on nanozyme release and intracellular distribution, murine
macrophages were pre-incubated with 500 ng/ml LPS and 200 ng/ml IFN-γ for 24 hours.
Amount of accumulated nanozyme was normalized for protein content and expressed in µg
of enzyme per mg of the protein as means ± SEM (n = 4).
Isolation of Nanozyme Released in Exosomes from Macrophages
Murine macrophages were preloaded with fluorescently-labeled nanozyme for 1 hour (0.5
mg/ml protein, Z=1), washed three times with PBS, and fresh media was added to the cells.
Media was collected after 2 hours, and exosomes with encapsulated nanozyme were purified
using Exoquick Exosome Precipitation Solution (System Biosciences, Mountain View, CA).
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Isolated exosomal fraction was added to CATH.a neurons and dynamics of nanozyme
accumulation in target cells were visualized by confocal microscopy.
Transmission Electron Microscopy (TEM)
A drop of isolated exosomal fraction with incorporated nanozyme in PBS was placed on
Formvar®-coated copper grid (150 mesh, Ted Pella Inc., Redding, CA). The dried grid
containing exosomes were stained with vanadyl sulfate and visualized using a Philips 201
transmission electron microscope (Philips/FEI Inc., Briarcliff Manor, NY).
Murine macrophages were pre-loaded with gold nanoparticles for one hour, washed, and
cocultured with CATH.a neurons for 18 hours. Following incubation, the cell samples were
conventionally prepared, and visualized by FEI Quanta 200 SEM equipped with Bruker
AXS Quantax XFlash 4010 x-ray microanalysis detector.
Fluorescence Activated Cell Sorting (FACS)
Amount of fluorescently labeled nanozyme accumulated in target cells was measured by
FACS. Typically, monolayers of HBMEC seeded in 6-well plates (1×106 cells/well) were
allowed to attach overnight, and then incubated for various time intervals with human
macrophages (1×106 cells/well) loaded with catalase nanozyme or identical concentration of
free nanozyme (without macrophages) as previously reported [15]. To evaluate involvement
of chemichannels in nanozyme transfer, target CATH.a neurons were pre-incubated in PMA
(300 nM) for one hour and then cocultured with murine macrophages preloaded with RITC-
labeled nanozyme with or without PMA in the media for another two hours. Following
incubation, cells were collected, and the amount of accumulated nanozyme in target cells
was assessed by FACS. To distinguish between the carrier cells and target cells, human or
murine macrophages were labeled prior to the addition to the receiver cells with Alexa
Fluor-647-conjugated anti-CD14 or CD11b, respectively.
Neuronal Survival Studies
CATH.a neurons cultured in 6-well plates (1×106 cells/well) were incubated with 500 µM 6-
hydroxydopamine (6-OHDA) and murine macrophages loaded with nanozyme, or the same
concentration of free nanozyme (without carrier cells) for four hours. Prior to the addition,
murine macrophages were incubated with catalase nanozyme (0.5 mg/ml, the highest non-
toxic concentration of nanozyme) as previously reported [13]. At these levels, 1 × 106
macrophages resuspended in 1 ml of the media accumulated about 25 µg of nanozyme.
Following incubation, all cells were collected, washed, stained with Alexa Fluor-488 LIVE/
DEAD dye according to manufacturer’s protocol, and the amount of LIVE/DEAD dye
accumulated in the recipient cells was assessed by FACS. To distinguish between the carrier
cells and target cells, murine macrophages were labeled with Alexa Fluor-678-conjugated
anti-CD11b prior to the addition [15]. The neuronal survival was expressed as percentage of
control CATH.a neurons that were incubated in neuronal complete media.
Gold Nanoparticles Preparation
Gold nanoparticles were prepared by mixing of 25 ml HAuCl4 (0.5 mM) water solution with
25 ml Pluronic block copolymer F127 (10 mM) solution. The mixture was incubated at
55°C for 2 hours and the obtained nanoparticles were separated by centrifugal filtration at
1500 RPM using a filter with 100 kDa cutoff. Effective hydrodynamic diameter and zeta-
potential of gold nanoparticles were measured by photon correlation spectroscopy using
‘ZetaPlus’ Zeta Potential Analyzer (Brookhaven Instruments, Santa Barbara, CA). The
average diameter was 66.46± 0.52nm, the polydispersity index (PDI) value was 0.073±
0.004 nm and z-potential was −30.47± 1.76 nm.
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For the all experiments, data are presented as the mean ± SEM. Tests for significant
differences between the groups were performed using a one-way ANOVA with multiple
comparisons and post-hoc Fisher's pairwise comparisons using GraphPad Prism 5.0
(GraphPad software, San Diego, CA). A minimum p value of 0.05 was estimated as the
significance level for all tests.
RESULTS
Mechanism of entry, intracellular trafficking, and release of nanozyme in i) cell carriers,
macrophages, and ii) receiver cells, neurons and brain microvessel endothelial cells, were
investigated.
I. Cell Carriers: Nanozyme Entry and Intracellular Trafficking in Macrophages
For optimal therapeutic efficacy of cell-based drug delivery, nanomaterials require specific
intracellular entry and organelle localization. These are linked to particle size, shape,
material composition, surface chemistry, and charge [23]. To these ends, we examined how
nanozymes enter and traffic in macrophages through employing specific inhibitors and by
colocalization of the nanozyme with specific intracellular compartments. Because murine
neurons and human brain microvessel endothelial cells were further used as receiver cells,
both murine bone marrow derived macrophages (BMM) and human monocyte derived
macrophages (MDM) were examined in this study.
Internalization—Mononuclear phagocytes (MP; monocytes, macrophages, and dendritic
cells) demonstrate robust phagocytic activity with engagement of the scavenger receptor
[24]. Following internalization, phagosomes fuse with lysosomes, where cargos are
efficiently degraded [24]. To assess this pathway, the effect of inhibitors of phagocytosis
and its scavenger receptor (cytochalasin b and polyinosinic acid [25], respectively) on
nanozyme accumulation in macrophages was evaluated. To ensure inhibition of
phagocytosis, disruption of actin microfilaments in treated cells was visualized with Alexa
Fluor-488-phalloidin (Figure S1). No significant effect on nanozyme uptake in BMM was
found by phagocytosis and scavenger receptor inhibition (Figure 1A). This supports a
phagocytosis-independent pathway of nanozyme entry, and linked likely to relatively small
particle sizes and the stealth effects of the PEG corona.
It is well known that nanoparticles under 500 nm may enter the cells by clathrin-dependent
and/or clathrin-independent endocytosis [23]. The latter processes include caveolae-
mediated endocytosis, macropinocytosis, and caveolae-independent endocytosis.
Noteworthy, a fraction of the vesicles within the cell matures into recycling endosomes, and
is transported back to the plasma membrane [26]. To examine the role of these pathways for
nanozyme entry, specific inhibitors of endocytosis were employed. Because most of
inhibitors are not specific for the particular route of internalization, parallel experiments
with a range of inhibitors was employed for the each type of endocytosis. Pretreatment with
inhibitors of clathrin-mediated endocytosis, sucrose or dansylcaverdine, significantly
(~50%) decreased accumulation of nanozyme in murine BMM, suggesting this process is
regulated by clathrin-coated pits (Figure 1A). Blocking caveolae formation with fillipin or
nystatin had lesser effect (~25% decrease) thus indicating less involvement of lipid rafts in
nanozyme entry.
Confocal microscopy supported these results (Figure 1B and C, Table 1). Colocalization of
nanozyme with transferrin (Tf), a marker of clathrin-coated pits [27], (20%–40% for all
studied time points, Figure 1B, Table 1) demonstrated clathrin-mediated endocytosis of the
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nanozyme. Colocalization with cholera toxin B (CTB), a caveolae marker [27], (1%–5%,
Figure 1C, Table 1) suggested that a caveolae-dependent pathway of nanozyme entry was
not a primary mechanism for entry. Similar results were obtained with antibody to clathrin
and caveolae proteins in human MDM providing cross validation for the murine studies
(Figure S2). Finally, inhibition of pinocytosis as well as macropinocytosis with colchicine
and rottlerin, respectively, resulted in a 35%-32% decrease in nanozyme accumulation
(Figure 1A). A major role of the clathrin-dependent pathway for the particles entry into
macrophages suggested that considerable portion of internalized nanoformulated catalase
may bypass lysosomal degradation, are sorted into recycling endosomes, and then released
in active form.
Intracellular trafficking—Intracellular localization of nanozyme in human (Figure 2, and
Table 1) and murine (Figure S3, and Table S1) macrophages were evaluated by staining
intracytoplasmic organelles that included the acidified endosomes, endoplasmatic reticulum
(ER), and mitochondria. Microphotographs demonstrated substantial colocalization of
nanozyme with Lysotracker (50%–60%, Figures 2 A and S3 A, Tables 1 and S1), and to a
lesser degree with ER- (10–18%, Figure 2 B and S3 B, Tables 1 and S1) and Mito-tracker
(10–18%, Figure 2 C and S3 C, Tables 1 and S1). Interestingly, nanozyme was relocated to
acidic endosomes from other cellular compartments at later time points (30–60 min, Table
1). Lysotracker staining allows the examination of nanoparticle intracellular localization in
live cells [28]. However, the marker stains all acidic compartments including lysosomes, late
endosomes and to some extent recycling endosomes. Therefore, to study nanozyme
localization in greater detail, specific staining with antibodies to early, late, or recycling
endosomes and lysosomes was performed in fixed human macrophages (Figure 3, Table 1).
Nanozyme accumulated largely in recycling endosomes as determined by anti-Rab11+
immunostaining (26%–47%, Figure 3 C, Table 1), followed in descending order of
accumulation by LAM 1+ lysosomes (11%–35%, Figure 3D, Table 1), Rab 7+ late
endosomes (10%–30%, Figure 3B, Table 1), and to a lesser degree in EEA1+ early
endosomes (5%–13%, Figure 3A, Table 1). Preferential compartmentalization of
nanoparticles within recycling endosomes and lysosomes is consistent with previous reports
for intracellular distribution of nanoformulated antiretroviral drugs and HIV-1 in human
macrophages [29].
Release—Inflammatory cells are known to shed small vesicles (exosomes), which play a
key role in intercellular communication [30]. Regarding macrophage-mediated delivery
system, we reported that nanozyme is transferred to target cells along with carrier cells
components including proteins and/or lipids [15]. Taken together, we hypothesized that
macrophages emit and/or transfer exosomes with encapsulated nanozyme to recipient cells.
To test this hypothesis, murine macrophages were preloaded with nanozyme, washed, and
supplemented with fresh media. Released exosomes were isolated and tested for catalase
activity. Significant enzymatic activity of catalase was detected in exosomal fraction (20,000
U/mL). Notably, in contrast to exosome-incorporated nanozyme, freshly prepared nanozyme
did not precipitate under these isolation conditions. TEM images revealed exosomes with
encapsulated nanozyme (Figure 4A).
Next, we reported nanozyme transport to contiguous target cells through bridging conduits
(BC), filopodia and elongated lamellipodia [15]. To this end, we examined nanozyme
colocalization with actin microfilaments, the main cytoskeleton components forming BC in
macrophages (Figure 4 C and D, Table 1). A remarkable effect of macrophage activation on
nanozyme intracellular localization was found within the carrier cells. Little overlap of
nanozyme and actin staining was demonstrated in non-activated macrophages (26%, Figure
4C, Table 1); contrastingly, in lipopolysaccharide (LPS)- and interferon gamma (IFN-γ)-
activated macrophages nanozyme was relocated to BC (61%, Figure 4D, Table 1). This was
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consistent with significant decrease in retained, and increase in released from macrophages
nanozyme upon activation (Figure 4B), suggesting a triggered mechanism of nanozyme
release from the carrier cells at the inflammation site.
II. Receiver cells: Nanozyme Entrance and Intracellular Trafficking in Neurons and Human
Brain Microvessel Endothelial Cells (HBMEC)
Internalization—We reported earlier that facilitated transport of the nanozyme from
macrophages to endothelial and neural target cells occurred through endocytosis-
independent mechanisms that involved fusion of cellular membranes of the donor and
receiver cells; wrapping of nanozyme into lipid coatings from the donor cell; and
development of macrophage bridging conduits and transport of nanozyme through
microtubules in macrophages [15]. Here we further elucidated mechanism of these
processes: i) release of nanozyme incorporated in exosomes from macrophages into
extracellular media; and ii) nanozyme transfer from macrophages to receiver cells through
BC, filopodia and lamellipodia.
To investigate the first pathway, murine macrophages were preloaded with fluorescently-
labeled nanozyme, washed, and supplemented with fresh media. Exosomes with
encapsulated nanozyme released to extracellular media from macrophages were harvested
and purified. Then, the isolated exosomal fraction was added to CATH.a neurons and the
dynamics of nanozyme accumulation within target cells were visualized by confocal
microscopy (Figure 5, Media S1). Images clearly demonstrated exosomes with encapsulated
nanozyme adsorbing on the surface of the recipient cells (Figure 5, arrowheads), and fusing
with the cellular membranes. Release of nanozyme into the cytoplasm of neurons resulted in
a diffuse fluorescent staining. We hypothesized that nanozyme incorporation into exosomes
improved drug binding with lipid membranes of the target cells. Adhered to the plasma
membranes exosomes fuse with them and discharge their cargo into target cells.
Furthermore, we evaluated intracellular trafficking of transported from macrophages
nanozyme in the receiver cells. Corroborative evidence of concurrent transfer of nanozyme
in exosomes was obtained when plasma membranes of macrophages preloaded with
fluorescently-labeled nanozyme were stained with antibody to CD14, and then added to
recipient human brain microvessel endothelial cells (HBMEC). Confocal microscopy
revealed vesicle-like inclusions with macrophages membranes staining (green) colocalized
with fluorescently-labeled nanozyme (red) in recipient HBMEC that was manifested in
yellow color (Figure 6A, arrowheads). This suggests that loaded in the carrier cells
nanozyme was incorporated into lipid-consisting vesicles, exosomes, and then transported
along with them into receiver cells.
Next, evaluation of intracellular trafficking of nanozyme in the receiver cells revealed
substantial colocalization of nanozyme with tubulin in HBMEC (45%–58%, Figure 6B,
Table 2) suggesting that these components of the cytoskeleton might be used as tracts for
nanozyme transport in the receiver cells. Interestingly, contrary to carrier cells, the
involvement of actin microfilaments in nanozyme transport was minimally detected in the
recipient cells (13%–19%, Figure 6C, Table 2).
Regarding the second pathway of nanozyme transfer through BC, the role of actual contact
between carrier and recipient cells was investigated. The two, left (A) and right (B) inserts
on Figure 7 represent sections of the confocal image at higher magnification taken from the
close (A) or distant (B) to the donor-receiver contact site. Confocal microphotographs
revealed initial localized distribution of nanozyme in the recipient cells at the sites of their
contact with the donor human macrophages (Figure 7A). At the same time, sites distant from
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the cell-cell contact points showed substantially less nanozyme accumulation (Figure 7B),
signifying a crucial role of cell-to-cell contact in this transfer.
As Gap junction channels formed by protein subunits, connexins, are conduits for the direct
cell-to-cell exchange of various molecules [31] between the cytoplasm of two cells, we
examined whether nanozyme transfer occurs through this pathway by inhibiting connexin 43
gap junction intercellular communications with the phorbol ester, 12-O-
tetradecanoylphorbol-13-acetate (PMA) [32]. Preloaded with nanozyme, murine
macrophages were divided into two groups and incubated with CATH.a neurons in the
presence or absence of PMA. No significant effect of gap junction assembly inhibition on
nanozyme accumulation in the receiver cells was found (Table S2), suggesting a gap
junction-independent pathway of nanozyme entry, probably due to the relatively large
particle size and nanozyme inclusion in exosomes.
Intracellular trafficking—Intracellular localization of macrophage-derived and
transferred nanozyme was examined and compared with the distribution of cell-free
nanozyme in target HBMEC (Figure 8) and CATH.a neurons (Figure 9). Major differences
in the accumulation levels and trafficking of nanozyme were observed for cell-derived and
cell-free nanozyme. First, the amount of nanozyme transferred from macrophages to target
endothelial cells and neurons (Figures 8 and 9, Set I) was substantially greater than that
from free nanozyme (Figures 8 and 9, Set II), which is consistent with our previous report
[15]. Second, nanozyme transferred from macrophages diffused throughout the entire target
cell demonstrating strong colocalization with endosomal compartments (especially, late and
recycling endosomes, and lysosomes) as well as mitochondria, and ER (Figure 8, Set I,
Table 2). Notably, the considerable colocalization with the late endosomal marker, Rab 7,
might in part be due to the expression of this protein in exosomes containing nanozyme that
were shed from macrophages and then internalized into HBMEC [33]. In contrast, free
nanozyme was localized mostly in early endosomes and then sorted to lysosomal
compartments (Figure 8, Set II, Table 2). Important differences in intracellular localization
reflect rather unique trafficking of nanozyme from macrophages to target cells than greater
accumulation levels. Thus, similar restricted localization of free nanozyme in lysosomal
compartments was demonstrated when HBMEC were incubated with a four-fold higher
concentration of nanozyme in the media (Figure S4).
III. Therapeutics
Facilitated nanozyme access to target endothelial cells compared to free nanozyme might
result in the greater BBB transport and consequently improved therapeutic effect.
Accordingly, levels of nanozyme accumulation in HBMEC transferred from carrier cells or
from the media were assessed by FACS. Indeed, significantly greater accumulation levels of
macrophage-mediated nanozyme transfer compared to free nanoparticles were demonstrated
(Figure 10A).
Furthermore, given the increased nanozyme transport from murine macrophages to CATH.a
neurons and the efficient ROS elimination when compared to free nanozyme [15], we
hypothesized that cell-derived nanozyme may increase neuronal survival upon oxidative
stress. To test this hypothesis, the effect of nanozyme-loaded murine macrophages on
neuronal survival was evaluated with 6-hydroxydopamine (6-OHDA)-treated CATH.a, an in
vitro model which recapitulates components of PD neurodegeneration. Nanozyme loaded in
murine macrophages has greater neuroprotective activity than the identical concentrations of
free enzyme (Figure 10B), probably, due to the greater nanozyme intracellular levels as well
as diffused intracellular distribution with favorable access to mitochondria in the target
neuronal cells.
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Macrophage-mediated transfer of nanoformulated catalase to endothelial cells and neurons
permits highly efficient drug delivery [13, 15, 34]. Notably, this activity is not specific for
nanozymes but can apply to other nanoparticles therapeutic systems. Thus, transfer of gold
nanoparticles with the same size as the nanozyme (~60 nm) and PEG corona from preloaded
murine macrophages (Figure S5A) to adjacent CATH.a neurons (Figure S5B) was
demonstrated by TEM. Interesting, nanoparticles transferred from macrophages were
localized largely in the cytoplasm of contacted neurons (Figure S5 B). In contrast,
nanoparticles accumulated from the media were localized in endocytic vesicles (Figure S5
C). Until now, it was not clear how cell based drug carriers improve disease outcomes from
nanoparticles administered alone. Herein, we uncovered intracellular trafficking of
nanozyme from macrophages to neurons and brain microvessel endothelial cells that are
intimately involved with one another and in the pathobiology of neurodegenerative
disorders.
There are several requirements for successful cell-based drug carriage. First, drug
nanoparticles should exploit intracellular entry and trafficking routes that avoid their rapid
degradation. Macrophages have evolved a variety of strategies to internalize pathogens,
particles and solutes. Each can enter through a range of mechanisms that include
phagocytosis, receptor-mediated endocytosis, and pinocytosis [24]. Pinocytosis and
receptor-mediated endocytosis share clathrin-based mechanisms and can readily occur
independently of actin polymerization. By contrast, phagocytosis occurs through cell uptake
of larger particles (>0.5 µm) by a clathrin-independent mechanism and targets degradation
into lysosomes. In the current works nanozymes entered macrophages principally through
clathrin-coated pits consistent with what was found recently by nanoformulated
antiretroviral drugs in human macrophages [29]. Accordingly, inhibition of pinocytosis and
macropinocytosis diminish nanozyme accumulation, contrary to the luck of the effect of
phagocytosis inhibition.
Clathrin-coated vesicles containing nanozyme undergo fusion with early sorting endosomes
following downstream sorting to late and recycling endosomes, and lysosomes.
Colocalization of particles with the ER and mitochondria was limited. The predominant
accumulation of nanozyme in recycling endosomes over lysosomes support the preservation
of catalase enzymatic activity against degradation in carrier cells and its substantial
extracellular release or into adjacent target cells. Noteworthy, a buffering effect of
nanozyme that increases lysosomal pH as previously reported [14] provides additional
preservation of catalase. As a result, such trafficking provides for non-degraded cargoes that
carry functionally-active enzymes capable of biologic responses during disease.
Release of nanozyme from macrophages occurs through BC with the engagement of actin
microfilaments. Importantly, activation of macrophages with LPS and IFN-γ that reflect, in
part, the inflammatory environment during progressive neurodegenerative diseases, resulted
in nanozyme relocation from endocytic compartments into the BC, thus supporting the
triggered release of nanozyme at the sites of active inflammation.
Intercellular exchange of organelles and proteins is also a known mechanism of cell
communication [29, 35–37]. Indeed, HIV-1 spreads from infected to uninfected cells
through BC and endocytic trafficking [29, 38]. Following entry, a portion of HIV-1
constituents are sorted into non-degrading endocytic compartments (early and recycling
endosomes), then shuttled through nanotubes to uninfected cells. Herein, we examined
whether the same trafficking mechanism is involved in macrophage-mediated nanozyme
transfer to neighboring cells. Besides BC development, macrophages constitutively secrete
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small vesicles, exosomes, affecting the physiology of neighboring recipient cells that acquire
new receptors, enzymes or genetic material [30, 39]. We reported the co-transport of
nanozyme and lipids from macrophages into brain microvessel endothelial and neuronal
targets [15]. We hypothesized that nanozyme transfers from macrophages via exosomes
facilitates plasma membrane penetration and orchestrates nanozyme intracellular trafficking
in recipient cells. Indeed, the mechanism of cell-derived nanozyme entry and intracellular
trafficking in adjacent target cells differs from the uptake of cell-free nanoparticles in
divergent ways. First, levels of nanozyme accumulated from macrophages to brain
microvessel endothelial and neural cells were greater than the amount of cell-free nanozyme
accumulated from the media. Second, confocal images demonstrate diffuse distribution of
nanozyme transferred from macrophages, in contrast to cell-free nanozyme localized in
endosomal compartments, mainly in lysosomes and early endosomes. This might be due to
encapsulation of nanozyme into exosomes from carrier cells that allows their efficient fusion
with plasma membranes of target cells and stable intracellular localization. Given strong
colocalization of nanozyme with tubulin microfilaments in microvessel endothelial cells, we
hypothesized that exosomes with incorporated nanozyme travel from macrophages to target
cells alongside tubulin tracts. This mechanism enables them to reach different intracellular
compartments such as mitochondria, cytoplasm, and ER, where ROS may be efficiently
deactivated as no involvement of gap junction channels in this transfer was found (Figure
11).
We posit that unique nanozyme trafficking from nanozyme carrier cells plays a key role in
the therapeutic effects of the enzyme in recipient cells. Indeed, increased neuronal survival
in the presence of nanozyme-loaded murine macrophages demonstrated significant
improvements against oxidative stress compared to cell-free nanozyme. In addition,
association of enzymes with lipid bilayers (e.g., the surface of liposomes) was demonstrated
to improve their stability and resistance to inactivation at low pH or high concentration of
H2O2 [40]. A similar stabilization effect might take place upon incorporation of nanozyme
into exosomes. Furthermore, macrophages loaded with nanozyme promote its accumulation
in brain microvessel endothelial cells, which in addition may improve its transport across the
BBB. In fact, this study suggests that macrophages can provide a shuttle service to facilitate
transport of therapeutic proteins that hitch hike onto the cells to the disease sites.
Any drug delivery system needs to be efficient, safe, and limit secondary tissue toxicities.
We previously demonstrated that using cells as delivery vehicles enables targeted drug
transport, and prolonged circulation times, along with minimizing systemic adverse effects
with targeted delivery [12, 13, 34]. The current study revealed mechanisms for these effects
on a cellular level indicating for the first time that macrophages improve entry and
intracellular drug distribution in target cells (Figure 11) resulting in superior therapeutic
effect. Furthermore, better understanding of macrophage-mediated facilitated transfer
mechanisms allows utilizing this system more efficiently. In particular, activation of
macrophages with specific agents may significantly improve ability of exosomes to adhere
and fuse with the cellular membranes of the target cells, and therefore, enhance the
therapeutic effect of the drug formulation. Finally, an ideal drug nanocarrier for cell-
mediated delivery should target specific intracellular pathways and compartments, for
example, recycling endosomes in the cell carriers, mitochondria and cytoplasm in neurons,
or endosomes involved in transcytosis within brain microvessel endothelial cells. Such drug
particle trafficking would ultimately increase the therapeutic index and improve disease
outcomes.
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Using macrophages for drug delivery enables targeted drug transport, and prolonged
circulation times, along with reductions in cell and tissue toxicities. The cells migrate
across impermeable barriers and can release drug cargo at sites of infection or tissue
injury. In addition, these cells are capable of cell-to-cell transmission of drug-laden
nanoparticles improving their therapeutic outcomes. Indeed, there are several limitations
related to the efficient drug loading in cell carriers, triggered release, ability of
macrophages to reach the damaged region of the brain in meaningful levels, as well as
efficient protection of the drug inside the cells-carriers against degradation. Nevertheless,
our data indicate that choosing a right formulation for a drug, along with an optimal cell-
carrier can accomplish these goals. Such systems for drug carriage and targeted release
represent a novel disease combating strategy being applied to a spectrum of human
disorders.
EXECUTIVE SUMMARY
• Overall Summary. Drug-carrier cells, macrophages, support transfer of
nanoformulated catalase, “nanozyme”, to adjacent brain microvessel endothelial
cells and neurons by endocytosis-independent mechanisms. The transported
nanozyme showed diffused intracellular distribution throughout the recipient
cells in contrast to macrophage-free nanozymes that were localized in lysosomes
following endocytic entry.
• Cell Carriers: Nanozyme Entry and Intracellular Trafficking in
Macrophages. Nanozyme enters to macrophages mainly in clathrin-coated
vesicles that undergo fusion with early sorting endosomes following
downstream sorting to late and recycling endosomes. This supports the
preservation of catalase enzymatic activity against degradation in carrier cells
and its substantial extracellular release or into adjacent target cells.
• Cell Carriers: Release. Triggered by inflammatory signals release of nanozyme
from macrophages occurs through bridging conduits with the engagement of
actin microfilaments.
• Receiver cells: Nanozyme Entrance and Intracellular Trafficking.
Nanozyme transfer from macrophages via exosomes facilitates plasma
membrane penetration and orchestrates nanozyme intracellular trafficking in
recipient cells.
• Therapeutics. A unique nanozyme trafficking from nanozyme carrier cells
facilitate neuroprotective responses and can improve clinical outcomes for
neurodegenerative diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Nanozyme entry into Macrophage occurs through clathrin-coated pits and caveolae-
mediated endocytosis
(A) Murine macrophages were exposed to fluorescently-labeled nanozyme in the presence
or absence of various inhibitors for 1 hour, and nanozyme uptake was analyzed by
fluorescence spectroscopy. (B, C) Murine macrophages were incubated for different times
with Alexa Fluor-649-labeled nanozyme, stained with FITC-Tf (clathrin-mediated
endocytosis marker, 25 µg/ml), or FITC-CTB (caveolae-mediated endocytosis marker, 25
µg/ml), and colocalization with nanozyme was evaluated by confocal microscopy. Refer also
to Table 1 for quantative colocalization. Statistical significance of nanozyme uptake in the
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presence of the inhibitors compared to murine macrophages in assay buffer is shown by
asterisks (**) p<0.005. Data represent means ± SEM (N = 4). Bar = 20 µm.
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Figure 2. Nanozyme intracellular localization in live human macrophages
The cells were incubated with nanozyme for different times and stained with (A)
LysoTracker Green (20 nM), (B) ERTracker Green (1 µM), or (C) MitoTracker Green (50
nM). Colocalization of nanozyme (red) and compartment staining (green) manifested in
yellow. Nanozyme accumulated largely in acidified compartments, and at substantially
lesser degree in ER and mitochondria. Refer also to Table 1 for quantative colocalization.
Bar = 20 µm.
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Figure 3. Localization of nanozyme in endosomal compartments in fixed human macrophages
Human monocyte-derived macrophages (HMDM) were incubated with nanozyme for
different times, fixed, permeabilized, and stained with (A) FITC-conjugated EEA1
monoclonal antibody (to early endosomes), (B) mouse monoclonal antibody Rab7 (late
endosomes), (C) mouse monoclonal antibody Rab11 (recycling endosomes), or (D) FITC-
conjugated LAMP 1 monoclonal antibody (to lysosomes). In case of non-labeled primary
mouse antibody (B, C), cells were further stained with FITC-conjugated secondary goat
anti-mouse immunoglobulin G. Colocalization of nanozyme (red) and compartment staining
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(green) manifested in yellow. Refer also to Table 1 for quantative colocalization. Bar = 20
µm.
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Figure 4. Release of nanozyme from macrophages in exosomes through BCs
Murine macrophages were loaded with nanozyme for one hour, washed, cultured in fresh
media and exosomes purified from media after cetrifugation. Exosomes with encapsulated
nanozyme were visualized by TEM (A). Bar = 100 nm. Relocation of nanozyme into in
BMM upon activation with 500 ng/ml LPS and 200 ng/ml IFN-γ was documented by
confocal microscopy (C, D). Murine macrophages were loaded with Alexa Fluor-675-
labeled nanozyme and stained with phalloidin-488 for actin microfilaments. No overlap of
nanozyme with actin microfilaments in macrophages was found in non-activated
macrophages (C). Substantial nanozyme relocation to BCs in macrophages (manifested in
yellow staining) occurred upon activation (D). Bar = 20 µm. This was confirmed by the
levels of nanozyme retained in macrophages and released into the media. Nanozyme was
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quantified by fluorospectrophotometry (B). Refer also to Table 1 for quantative
colocalization.
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Figure 5. Dynamics and localization of nanozyme transported in exosomes from murine
macrophages to CATH.a neurons
Confocal images of CATH.a neurons incubated with nanozyme (red)-containing exosomes
released from preloaded murine macrophages. The first and last time fluorescence images
are shown merged with differential interference contrast (DIC) microscopy. Exosomes in the
media with encapsulated nanozyme were adsorbed on the surface of the recipient cells
(shown by arrowheads) and fused with the membranes, releasing nanozyme into the
cytoplasm of neurons that resulted in diffuse fluorescent staining. Bar = 20 µm.
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Figure 6. Nanozyme transfer from human macrophage exomes to HBMEC
HBMEC were incubated for one hour with human macrophages preloaded with nanozyme
(red), fixed, permeabilized, and stained with anti-tubulin (green) (B), or phalloidin-488 to
actin microfilaments (green) (C). In separate experiments, nanozyme-loaded macrophages
were labeled with Alexa Fluor-488-anti-CD14 (green) (A) and then added to HBMEC.
Images revealed substantial nanozyme colocalization in HBMEC with compartments from
HMDM (A), and tubulin (B) (manifested in yellow) suggesting that nanozyme was
transferred from carrier cells in exosomes alongside the tubulin microfilaments. Low
colocalization of nanozyme with actin microfilaments was found in recipient cells (C).
Exosomes from macrophages in HBMEC (A) and loaded macrophages (B, C) are shown by
arrows. Bar represents 20 µm.
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Figure 7. Nanozyme localized intracellular distribution in HBMEC transferred from the carrier
cells, human macrophages
Human macrophages preloaded with fluorescently-labeled nanozyme were incubated with
HBMEC for 30 min. Nanozyme was transferred to the receiver cells at the sites of cell-cell
contact with the carrier cells (A) in contrast to low accumulation levels at the sites distant
from the cell contact (B). Bar represents 20 µm.
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Figure 8. Intracellular localization of cell-derived or cell-free nanozyme within HBMEC
HBMEC were incubated for 30 min with (I) human macrophages preloaded with nanozyme,
or (II) cell-free nanozyme (without carrier cells), fixed, permeabilized, and stained with (A)
FITC-conjugated EEA1 monoclonal antibody (to early endosomes); (B) mouse monoclonal
antibody Rab7 (late endosomes); (C) FITC-conjugated LAMP 1 monoclonal Ab (to
lysosomes); (D) mouse monoclonal antibody to Rab11 (recycling endosomes); (E)
Mitotracker Green; (F) ER Tracker Green. Cells labeled with unconjugated primary mouse
antibody (B, C) were stained with FITC-conjugated secondary goat anti-mouse
immunoglobulin G. To distinguish between carrier cells and target cells, human
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macrophages were labeled with Alexa Fluor-405-conjugated anti-CD14 (blue) (A, E).
Colocalization of nanozyme (red) and compartment staining (green) was manifested in
yellow. Human macrophages are shown by arrowheads. Refer also to Table 2 for
quantitative colocalization. Bar = 20 µm.
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Figure 9. Intracellular localization of cell-derived or cell-free nanozyme within CATH.a neurons
CATH.a neurons were incubated for 18 hours with (I) murine macrophages preloaded with
nanozyme, or (II) cell-free nanozyme (without carrier cells), washed and stained with (A)
Mitotracker green; (B) ER tracker Green; or (C) Lysotracker green. Colocalization of
nanozyme (red) and compartment staining (green) is shown in yellow. Murine macrophages
are shown by arrowheads. Refer also to Table 2 for quantative colocalization. Bar = 20 µm.
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Figure 10. Superior transport and neuroprotective activity of nanozyme loaded in macrophages
compared to cell-free nanozyme
(A) Effect of nanozyme loading into human macrophages on its accumulation in HBMEC:
the recipient cells were incubated with cell free nanozyme or exposed to macrophages
loaded with fluorescently-labeled nanozyme for four hours. Following incubation, the cells
were collected and the amount of nanozyme accumulated in HBMEC was determined by
FACS. (B) Effect of nanozyme loading into murine macrophages on its neuroprotective
activity in in vitro PD model: CATH.A neurons were incubated with 6-OHDA in the
presence of murine macrophages loaded with nanozyme or the same amount of free
nanozyme for four hours. Following incubation, the cells were washed, stained with LIVE/
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DEAD dye and neuronal survival accessed by FACS. Data are expressed as % of control
cells cultured in the media. To distinguish between the carrier cells and target cells, human
and murine macrophages were labeled with Alexa 678-conjugated Ab to CD 14 and CD
11b, respectively, prior to the addition. Results from N=4 wells (± SEM) clearly
demonstrated that transport to HBMEC (A), and neuroprotective activity (B) of nanozyme
from the cell-carriers, were substantially greater, compared to the transport and activity of
free nanozyme.
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Figure 11. Nanozyme intracellular localization in recipient cells transferred from carrier cells or
from media
Encapsulation of nanozyme into exosomes from the carrier cells allowed their efficient
fusion with the plasma membranes of target cells, and favorable intracellular localization in
contrast to free nanozyme taken from the media and accumulated in endosomal
compartments. Exosomes with incorporated nanozyme travel in target cells using them like
tracks.
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Table 1
Evaluation of Nanozyme Entrance, Intracellular Trafficking, and Release by % Colocalization with Specific
Intracellular Compartments in Carrier Cells, Human Macrophages
Organelle 5 min 15 min 30 min 60 min
Entrance
clatrin-coated pits 35.1 ± 2.2b 29.0 ± 1.1 21.6 ± 3.4 43.0 ± 3.9
caveolae 4.9 ± 1.9 2.2 ± 1.2 2.9 ± 0.2 1.3 ± 0.2
Intracellular trafficking
Acidic organelles 49.5 ± 6.2 56.6 ± 4.1 58.4 ± 3.4 61.0 ± 3.9
ER 18.3 ± 5.0 10.2 ± 4.9 14.6 ± 1.4 16.8 ± 1.5
Mitochondria 12.5 ± 1.6 9.7 ± 1.0 18.5 ± 2.3 17.0 ± 2.0
Early endosomes 13.0 ± 4.9 4.68 ± 2.2 7.2 ± 1.4 9.0 ± 0.8
Late endosomes 13.4 ± 1.5 9.9 ± 1.7 30.0 ± 3.8 24.7 ± 3.2
Recycling endosomes 35.0 ± 1.5 26.1 ± 2.2 26.2 ± 2.1 47.4 ± 9.5
Lysosomes 23.4 ± 6.7 11.13 ± 1.9 19.6 ± 3.8 35.8 ± 4.9
Release a
non-activated activated with LPS and IFN-γ
Actin microfilaments    26.1 ± 0.1 79.1 ± 7.2
a
nanozyme-preloaded murine macrophages were incubated with CATH.A neurons for 18 hours
b
Data represent means ± SEM (N = 40).
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Table 2
Evaluation of Nanozyme Entrance and Intracellular Trafficking by % Colocalization with Specific
Intracellular Compartments in in Target Cells, HBMEC
Organelle from macrophagesa free, from media
30 min 60 min 30 min 60 min
Entrance
actin 13.1 ± 2.5 b 19.0 ± 1.4 n/a n/a
tubulin 58.0 ± 4.3 44.5 ± 2.5 n/a n/a
Intracellular trafficking
ER 9.6 ± 21.7 16.3 ± 1.0 18.7 ± 1.9 19.1 ± 1.0
Mitochondria 8.9 ± 1.1 6.9 ± 0.7 1.1 ± 0.3 0.7 ± 1.4
Early endosomes 4.2 ± 0.9 (*) 17.2 ± 1.6 (*) 15.2 ± 3.3 26.9 ± 1.7
Late endosomes 29.5 ± 1.4 (**) 22.4 ± 1.3 (**) 4.3 ± 0.7 12.2 ± 2.1
Recycling endosomes 9.5 ± 1.4 (*) 11.8 ± 1.1 (*) 4.4 ± 0.4 19.7 ± 2.1
Lysosomes 9.6 ± 2.4 (*) 11.0 ± 2.0 (*) 27.8 ± 4.4 19.4 ± 2.4
a
Statistical significance compared to colocalization levels of macrophages-free nanozyme accumulated from the media is shown by asterisk:
p<0.05 (*); p<0.005 (**).
b
Data represent means ± SEM (N = 40).
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